辉瑞-BioNTech和Moderna疫苗对≥65岁成人COVID-19住院的保护效果
该研究在美国14个州24家医院评估了辉瑞-BioNTech或Moderna疫苗对≥65岁成人COVID-19相关住院的保护效果。纳入417名住院成人(187例病例和230名对照),完全接种的调整疫苗有效性为94%(95%CI=49%-99%),部分接种为64%(95%CI=28%-82%)。
要点
- ≥65岁成人完全接种后预防COVID-19住院的调整VE为94%(95%CI=49%-99%)。
- 部分接种的调整VE为64%(95%CI=28%-82%)。
- 真实世界数据支持疫苗接种降低高龄人群重症COVID-19风险。
核心结论
- 辉瑞-BioNTech或Moderna疫苗在真实世界条件下对≥65岁成人COVID-19相关住院提供保护。
研究设计与样本
- 在美国14个州24家医院进行的多中心评估,纳入417名≥65岁住院成人(187例病例和230名对照)。
主要发现
- 完全接种的调整VE为94%(95%CI=49%-99%),部分接种为64%(95%CI=28%-82%)。
- 研究对象中位年龄73岁,48%为女性,73%为非西班牙裔白人,17%为非西班牙裔黑人,6%为西班牙裔,4%居住在长期护理机构。
临床怎么用
- 应重视≥65岁成人疫苗接种以降低COVID-19相关住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first COVID-19 vaccines approved for use under an Emergency Use Authorization (EUA) in the United States (1-3). In an evaluation at 24 hospitals in 14 states,* the effectiveness of partial or full vaccination† with Pfizer-BioNTech or Moderna vaccines against COVID-19-associated hospitalization was assessed among adults aged ≥65 years. Among 417 hospitalized adults aged ≥65 years (including 187 case-patients and 230 controls), the median age was 73 years, 48% were female, 73% were non-Hispanic White, 17% were non-Hispanic Black, 6% were Hispanic, and 4% lived in a long-term care facility. Adjusted vaccine effectiveness (VE) against COVID-19-associated hospitalization among adults aged ≥65 years was estimated to be 94% (95% confidence interval [CI] = 49%-99%) for full vaccination and 64% (95% CI = 28%-82%) for partial vaccination. These findings are consistent with efficacy determined from clinical trials in the subgroup of adults aged ≥65 years (4,5). This multisite U.S. evaluation under real-world conditions suggests that vaccination provided protection against COVID-19-associated hospitalization among adults aged ≥65 years. Vaccination is a critical tool for reducing severe COVID-19 in groups at high risk.
引用
- Tenforde MW, Olson SM, Self WH, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33956782. doi:10.15585/mmwr.mm7018e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。